Dr. Ron’s Research Review – January 2, 2019

©

This week’s research review focuses on burnout syndrome

Occupational burnout is thought to result from long-term, unresolvable job stress.
In 1974, Herbert Freudenberger characterized burnout by a set of symptoms that includes exhaustion resulting from work's excessive demands as well as physical symptoms such as headaches and sleeplessness, "quickness to anger," and closed thinking. He observed that the burned out worker "looks, acts, and seems depressed". (Freudenberger, 1986)

Robuvit® (French oak wood extract)

A study evaluated the effect of supplementation with Robuvit® on the burnout syndrome (BOS) of patients with significant fatigue and high oxidative stress. Robuvit® (French oak wood extract) is a standardized supplement, effective in treating chronic fatigue syndrome (CFS), post-traumatic stress disorder (PTSD) and convalescence.  A group of 108 subjects with BOS, consisting of a subgroup of 42 young surgeons in training and a subgroup of 66 managers, were studied. Subjects followed a standard management (SM); one half of the subjects received 300 mg/day of Robuvit® for 4 weeks in addition to SM.  Robuvit® was (P<0.05) more effective compared to SM in improving parameters evaluated with the aid of Maslach Burnout Inventory: dealing with patients problems, improving the relationship with patients, decreasing emotional drainage and intolerance (P<0.05). The feeling of a positive influence improved. The decrease in strain from interactions at work, the decrease in the lack of care feeling, the improved levels in interest were all positively affected with Robuvit (P<0.05) in comparison with SM. The need for giving up decreased, the level of satisfaction improved and the regrets for being in the profession decreased. BOS symptoms were positively affected by the supplement (P<0.05). Oxidative stress (388;24 Carr Units decreased to 344;22 with Robuvit®; P<0.05), SM had no influence on oxidative stress. Robuvit® was also more effective in professionals with burnout syndrome than the SM only in in decreasing emotional drainage, fatigue and intolerance (P<0.05). Robuvit® significantly improved the feeling of having a positive influence (P<0.05). Also, Robuvit® significantly decreased the strain resulting from interactions at work and improved the care for colleagues/customers (P<0.05). Interest and enthusiasm were significantly increased in subjects taking Robuvit® in comparison with controls with standard management alone (P<0.05). The mean score of the desire to give up was decreased with Robuvit® in comparison with SM (P<0.05) and job satisfaction was significantly improved (P<0.05). The feeling of regrets of being in the profession was significantly reduced with the supplement in comparison to SM (P<0.05). Robuvit® reduced oxidative stress (P<0.05) from 397;33 to 323;29 Carr Units in comparison with a low decrease with SM (from 396;19 vs. 378;27) at 4 weeks. In conclusion, in this registry study on BOS, Robuvit® by controlling fatigue (the primary symptom) and oxidative stress, relieves the most important 'symptoms' associated with BOS. The effects are comparable in young surgeons not accustomed to stress, as well as in professionals in management positions who are used to control stress. (Belcaro et al., 2018)

TARGET 1

A study examined the efficacy and tolerability of TARGET 1® for professional fatigue syndrome (burnout) in a 12-week, double-blind, randomized, placebo-controlled trial. All participantswere affected by burnout syndrome based on a score of ≥4 on the Burnout Measure Scale (BMS-10). The primary outcome measure was the change in the BMS-10 score; secondary outcome measures included the change in the Maslach's Burnout Inventory scale-Human Service Survey (MBI-HSS) score and the Beck Depression Inventory. Five scores were evaluated.  Eighty-seven participants were enrolled in the study: 44 received the active formulation (verum group); 43 received placebo. After 12 weeks' supplementation, the placebo group showed significant improvements in scores for BMS-10, MBI-HSS fatigue and the Beck Depression Inventory, but MBI-HSS depersonalization and task management were not improved; the verum group showed significant improvements in all five scores. The verum group consistently showed significantly greater improvements in scores than the placebo group.  TARGET 1® significantly improved the symptoms of burnout after 12 weeks' use. (Jacquet et al., 2015)
TARGET 1 includes four key ingredients: casozepine (milk casein), which is considered in the French pharmacopoeia as having a benzodiazepine-like profile and an action that targets depressive symptoms, which are always present in burnout; extramel, a melon extract rich in an antioxidant (superoxide dismutase) that reduces cellular oxidation (which is accelerated in burnout due to sleep and mood disorders, cramp, fatigue, and stress);  taurine, which is believed to have energizing properties and ‘anti-fatigue’ effects;  Eleutherococcus senticosus, which is classified as an ‘adaptogenic herb’, a term applied to plants such as ginseng that increase the body’s resistance to stress (another constant feature of burnout).

 

Dr. Ron

 


Articles

 

Supplementation with Robuvit® in subjects with burnout associated to high oxidative stress.
(Belcaro et al., 2018) Download
BACKGROUND:  This supplement registry study evaluated the effect of supplementation with Robuvit® on the burnout syndrome (BOS) of patients with significant fatigue and high oxidative stress. Robuvit® (French oak wood extract) is a standardized supplement, effective in treating chronic fatigue syndrome (CFS), post-traumatic stress disorder (PTSD) and convalescence. METHODS:  A group of 108 subjects with BOS, consisting of a subgroup of 42 young surgeons in training and a subgroup of 66 managers, were studied. Subjects followed a standard management (SM); one half of the subjects received 300 mg/day of Robuvit® for 4 weeks in addition to SM. RESULTS:  Robuvit® was (P<0.05) more effective compared to SM in improving parameters evaluated with the aid of Maslach Burnout Inventory: dealing with patients problems, improving the relationship with patients, decreasing emotional drainage and intolerance (P<0.05). The feeling of a positive influence improved. The decrease in strain from interactions at work, the decrease in the lack of care feeling, the improved levels in interest were all positively affected with Robuvit (P<0.05) in comparison with SM. The need for giving up decreased, the level of satisfaction improved and the regrets for being in the profession decreased. BOS symptoms were positively affected by the supplement (P<0.05). Oxidative stress (388;24 Carr Units decreased to 344;22 with Robuvit®; P<0.05), SM had no influence on oxidative stress. Robuvit® was also more effective in professionals with burnout syndrome than the SM only in in decreasing emotional drainage, fatigue and intolerance (P<0.05). Robuvit® significantly improved the feeling of having a positive influence (P<0.05). Also, Robuvit® significantly decreased the strain resulting from interactions at work and improved the care for colleagues/customers (P<0.05). Interest and enthusiasm were significantly increased in subjects taking Robuvit® in comparison with controls with standard management alone (P<0.05). The mean score of the desire to give up was decreased with Robuvit® in comparison with SM (P<0.05) and job satisfaction was significantly improved (P<0.05). The feeling of regrets of being in the profession was significantly reduced with the supplement in comparison to SM (P<0.05). Robuvit® reduced oxidative stress (P<0.05) from 397;33 to 323;29 Carr Units in comparison with a low decrease with SM (from 396;19 vs. 378;27) at 4 weeks. CONCLUSIONS:  In conclusion, in this registry study on BOS, Robuvit® by controlling fatigue (the primary symptom) and oxidative stress, relieves the most important 'symptoms' associated with BOS. The effects are comparable in young surgeons not accustomed to stress, as well as in professionals in management positions who are used to control stress.


 

The issues of staff burnout in therapeutic communities.
            (Freudenberger, 1986)  Download
Burnout is a process that comes about as a consequence of a depletion of energies, as well as feelings of being overwhelmed with many issues that may confront an individual. It is the result of a person 's sense of dedication and commitment to a task or job, coupled with a need to prove oneself. In time, it impacts on a person's attitudes. perceptions and judgment. Burnout manifests itself in various symptoms ofa physical, mental, behavioral and/or emotional nature. It is also accompanied by a feeling of being overloaded, by loss of motivation that at one time served as a major stimulus, and a shift of attitude toward the residents and oneself.

Burnout: evaluation of the efficacy and tolerability of TARGET 1® for professional fatigue syndrome (burnout).
            (Jacquet et al., 2015) Download
OBJECTIVE:  To study the effect of a dietary supplement (TARGET 1®: a combination of casozepine, taurine, Eleutherococcus senticosus and extramel) on burnout symptomatology. METHODS:  A 12-week, double-blind, randomized, placebo-controlled trial was conducted in workers engaged in professional contact with patients, students or clients. All were affected by burnout syndrome based on a score of ≥4 on the Burnout Measure Scale (BMS-10). The primary outcome measure was the change in the BMS-10 score; secondary outcome measures included the change in the Maslach's Burnout Inventory scale-Human Service Survey (MBI-HSS) score and the Beck Depression Inventory. Five scores were evaluated. RESULTS:  Eighty-seven participants were enrolled in the study: 44 received the active formulation (verum group); 43 received placebo. After 12 weeks' supplementation, the placebo group showed significant improvements in scores for BMS-10, MBI-HSS fatigue and the Beck Depression Inventory, but MBI-HSS depersonalization and task management were not improved; the verum group showed significant improvements in all five scores. The verum group consistently showed significantly greater improvements in scores than the placebo group. CONCLUSIONS:  TARGET 1® significantly improved the symptoms of burnout after 12 weeks' use.


 

References

Belcaro, G, et al. (2018), ‘Supplementation with Robuvit® in subjects with burnout associated to high oxidative stress.’, Minerva Med, 109 (3), 211-17. PubMed: 29164838
Freudenberger, HJ (1986), ‘The issues of staff burnout in therapeutic communities.’, J Psychoactive Drugs, 18 (3), 247-51. PubMed: 3772650
Jacquet, A, et al. (2015), ‘Burnout: evaluation of the efficacy and tolerability of TARGET 1® for professional fatigue syndrome (burnout).’, J Int Med Res, 43 (1), 54-66. PubMed: 25537278